Cargando…

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance

With sunitinib treatment of metastatic renal cell carcinoma, most patients end up developing resistance over time. Recent clinical trials have shown that individualizing treatment protocols could delay resistance and result in better outcomes. We developed an in vivo xenograft tumor model and compar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Harrison Sicheng, Ding, Qiang, Lichner, Zsuzsanna, Kim, Sung Sun, Saleeb, Rola, Farag, Mina, Di Meo, Ashley, Plant, Pamela, Kaldas, Mirit, Bjarnason, Georg Arnold, Yousef, George Makram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779527/ https://www.ncbi.nlm.nih.gov/pubmed/35054064 http://dx.doi.org/10.3390/jcm11020369

Ejemplares similares

Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy
por: Saleeb, Rola M., et al.
Publicado: (2018)

Elucidating mechanisms of sunitinib resistance in renal cancer: an integrated pathological-molecular analysis
por: Butz, Henriett, et al.
Publicado: (2017)

miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/tumor initiating cell properties
por: Lichner, Zsuzsanna, et al.
Publicado: (2014)

Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial
por: Porta, Camillo, et al.
Publicado: (2012)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Neuropilin-1 is a receptor for extracellular miRNA and AGO2/miRNA complexes and mediates the internalization of miRNAs that modulate cell function
por: Prud'homme, Gerald J., et al.
Publicado: (2016)

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
por: Rovithi, Maria, et al.
Publicado: (2016)

Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis
por: Kang, Hee Jung, et al.
Publicado: (2020)

CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib
por: Haider, Masoom A., et al.
Publicado: (2017)

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
por: Di Paolo, Antonello, et al.
Publicado: (2017)

Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours
por: SAPONARA, MARISTELLA, et al.
Publicado: (2014)

Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction
por: Kleibeuker, Esther A, et al.
Publicado: (2015)

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings
por: Wilson, S, et al.
Publicado: (2015)

Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma
por: Kawashima, Atsunari, et al.
Publicado: (2018)

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma
por: Zhu, Xudong, et al.
Publicado: (2021)

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
por: Donskov, Frede, et al.
Publicado: (2015)

Second-line sunitinib for Chinese patients with advanced gastrointestinal stromal tumor: 37.5 mg schedule outperformed 50 mg schedule in adherence and prognosis
por: Zhang, Chenli, et al.
Publicado: (2021)

MRTF: Basic Biology and Role in Kidney Disease
por: Miranda, Maria Zena, et al.
Publicado: (2021)

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
por: Buti, Sebastiano, et al.
Publicado: (2017)

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
por: Khosravan, Reza, et al.
Publicado: (2016)

Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario
por: Allman, Kimberly D., et al.
Publicado: (2019)

Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study
por: Abdelaziz, Lobna A., et al.
Publicado: (2021)

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
por: Buti, Sebastiano, et al.
Publicado: (2018)

Does an Alternative Sunitinib Dosing Schedule Really Improve Survival Outcomes Over a Conventional Dosing Schedule in Patients with Metastatic Renal Cell Carcinoma? An Updated Systematic Review and Meta-Analysis
por: Chung, Doo Yong, et al.
Publicado: (2019)

Translational research in kidney transplantation and the role of patient engagement
por: Farragher, Janine F., et al.
Publicado: (2015)

A miRNA-based classification of renal cell carcinoma subtypes by PCR and in situ hybridization
por: Di Meo, Ashley, et al.
Publicado: (2017)

From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma
por: Arsanious, Androu, et al.
Publicado: (2009)

Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial
por: Cella, David, et al.
Publicado: (2014)

A 2/1 Sunitinib Dosing Schedule Provides Superior Antitumor Effectiveness and Less Toxicity Than a 4/2 Schedule for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Deng, Huan, et al.
Publicado: (2020)

Urachal xanthogranuloma: a rare but important case presenting as a urachal mass
por: Jain, Kunal, et al.
Publicado: (2023)

Sunitinib Induced Immune Thrombocytopenia
por: Shekarriz, Ramin, et al.
Publicado: (2015)

Sunitinib: the antiangiogenic effects and beyond
por: Hao, Zhonglin, et al.
Publicado: (2016)

Reversal of Cushing Pigmentation by Sunitinib
por: Iwasaki, Yorihiro, et al.
Publicado: (2019)

Sunitinib: Colitis: case report
Publicado: (2022)

Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
por: Maráz, Anikó, et al.
Publicado: (2018)

Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma
por: Zhang, Xingming, et al.
Publicado: (2018)

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
por: Gore, M E, et al.
Publicado: (2015)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_v6t0nb3aacbngtiv7a469hocp0